Hanmi Pharm acquires approval of hypertension/hyperlipidemia treatment

Published: 2017-07-18 14:11:21

Updated: 2017-07-18 14:11:21

Hanmi Pharm(CEO Jong-Soo Woo, Sae-Chang Kwon) announced on the 17^th that ‘Amosartan Q,’ a 3-substance combination drug with 2 antihypertensive substances and 1 anti-hyperlipidemia substance, was approved from the Ministry of Food and Drug Safety(MFDS) as a product.

Amosartan Q, an ETC drug in combination with the Hanmi Pharm’s representative combination antihypertensive ‘Amosartan(Amlodipin+Lo...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.